Europeanhhm

Tetris Pharma signs service agreement with Syneos Health

Wednesday, January 04, 2023

Tetris Pharma Ltd, a subsidiary of biopharmaceutical company, Arecor Therapeutics plc (AIM: AREC), today announces that it has signed a service agreement with Syneos Health®, the only fully integrated biopharmaceutical solutions organization purpose-built to accelerate customer success, to support the build out of Tetris Pharma’s commercial platform across Europe.

Through this partnership, Syneos Health will provide commercial support through an outsourced contract sales services to accelerate healthcare practitioner awareness of Tetris Pharma’s flagship product, Ogluo®, for people living with diabetes across initial launch territories.

Dr. Shafiq Choudhary, Managing Director, Tetris Pharma, commented:

“Following the recent launch of Ogluo® (glucagon prefilled autoinjector pen) in Germany, we are focused on continuing its accelerated roll-out across Europe. Syneos Health was one of several potential partners that were evaluated during the process of partnering with an organisation that would provide a multitude of commercial options to help establish the product across Europe. Partnering with Syneos Health, a leader in clinical research, medical affairs, and commercialisation services for the pharmaceutical industry, is key to building our reputation as specialists in the marketing, sales, and distribution of commercial-stage specialty hospital products across the UK and Europe.”

Harvard Medical School - Leadership in Medicine Southeast Asia47th IHF World Hospital CongressHealthcare CNO SummitHealthcare CMO Summit